Key facts
- It has raised $260K; the latest was Later Stage VC in Aug 2025.
- Notable investors include US National Science Foundation, United States Department of War, C2I Accelerator, National Center For Advancing Translational Sciences, National Eye Institute — 6 tracked in total.
- LayerBio has filed 2 Form Ds with the SEC since 2014, most recently Jun 2021 ($50K sold to 2 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for LayerBio
- ·The full record, as it builds
Funding rounds
No funding rounds for LayerBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LayerBio
Developer of novel therapies designed to address unmet needs in the field of ophthalmology. The company develops a novel bioerodible sustained-release technology for use with any standard intraocular lens in cataract surgery, enabling healthcare providers to have access to a device for continuous release of medications for treatment and prevention of postoperative complications of cataract surgery in patients.
- Sector
- Healthcare
- HQ
- Lexington, MA, United States
- Founded
- 2013
- Employees
- 3
- Website
- layerbio.com/
- Ownership
- Privately Held (backing)
LayerBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LayerBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LayerBio in its N-PORT filings yet. We sweep new filings monthly.